• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The expanding role of biologic therapy for IBD.

作者信息

Hanauer Stephen B

出版信息

Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):63-4. doi: 10.1038/nrgastro.2009.238.

DOI:10.1038/nrgastro.2009.238
PMID:20134483
Abstract
摘要

相似文献

1
The expanding role of biologic therapy for IBD.生物疗法在炎症性肠病治疗中的作用不断扩大。
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):63-4. doi: 10.1038/nrgastro.2009.238.
2
Future biologic targets for IBD: potentials and pitfalls.未来炎症性肠病的生物治疗靶点：潜力与陷阱。
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):110-7. doi: 10.1038/nrgastro.2009.218.
3
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.权衡炎症性肠病生物治疗的风险与益处。
Expert Opin Drug Saf. 2015;14(12):1915-34. doi: 10.1517/14740338.2015.1108961. Epub 2015 Nov 11.
4
Safety of infliximab and other biologic agents in the inflammatory bowel diseases.英夫利昔单抗及其他生物制剂在炎症性肠病中的安全性。
Gastroenterol Clin North Am. 2006 Dec;35(4):837-55. doi: 10.1016/j.gtc.2006.09.008.
5
Emerging biologic therapies in inflammatory bowel disease.炎症性肠病中的新兴生物疗法。
Rev Gastroenterol Disord. 2004 Spring;4(2):66-85.
6
More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease.
Dig Liver Dis. 2023 Feb;55(2):298-299. doi: 10.1016/j.dld.2022.11.004. Epub 2022 Nov 19.
7
Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.关注炎症性肠病抑制部位的炎症机制：当前及未来的治疗方法。
Gastroenterol Clin North Am. 2006 Dec;35(4):743-56. doi: 10.1016/j.gtc.2006.09.009.
8
Optimizing the safety of biologic therapy for IBD.优化 IBD 生物治疗的安全性。
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):93-101. doi: 10.1038/nrgastro.2009.221.
9
Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia.
Dig Liver Dis. 2018 Mar;50(3):314-317. doi: 10.1016/j.dld.2017.12.016. Epub 2017 Dec 24.
10
Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.择期炎症性肠病手术前的生物治疗管理。
Inflamm Bowel Dis. 2019 Sep 18;25(10):1613-1620. doi: 10.1093/ibd/izz002.

引用本文的文献

1
Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis.生物疗法在炎症性肠病风湿表现中的作用：一项系统分析。
Cureus. 2023 Sep 13;15(9):e45195. doi: 10.7759/cureus.45195. eCollection 2023 Sep.
2
Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.COVID-19 大流行对炎症性肠病患者的影响：当前证据综述。
World J Gastroenterol. 2021 Jul 7;27(25):3748-3761. doi: 10.3748/wjg.v27.i25.3748.
3
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.

本文引用的文献

1
Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations.评估类风湿关节炎患者的影像学测量：优势和局限性。
Rheum Dis Clin North Am. 2009 Nov;35(4):723-9, vi. doi: 10.1016/j.rdc.2009.10.005.
从原研英夫利昔单抗转换至英夫利昔单抗生物类似药或继续使用原研英夫利昔单抗的病情稳定患者的转换和停药模式
Biologics. 2021 Jan 6;15:1-15. doi: 10.2147/BTT.S285610. eCollection 2021.
4
Pharmacological Evaluation of TAK-828F, a Novel Orally Available RORγt Inverse Agonist, on Murine Colitis Model.TAK-828F，一种新型口服 RORγt 反向激动剂的药效学评价，在小鼠结肠炎模型中的作用。
Inflammation. 2019 Feb;42(1):91-102. doi: 10.1007/s10753-018-0875-7.
5
JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4 T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.JNK信号通路相关磷酸酶/DUSP22抑制CD4 T细胞活化及Th1/Th17细胞分化，并与炎症性肠病的临床活动呈负相关。
Front Immunol. 2017 Jul 4;8:781. doi: 10.3389/fimmu.2017.00781. eCollection 2017.
6
Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease.血清脂多糖和1,3-β-D-葡聚糖水平与克罗恩病患者的病情严重程度相关。
Mediators Inflamm. 2015;2015:843089. doi: 10.1155/2015/843089. Epub 2015 May 28.
7
Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa.英夫利昔单抗通过平衡肠道黏膜异常免疫反应，优先诱导伴有肠腔病变的短疗程克罗恩病实现临床缓解和黏膜愈合。
Mediators Inflamm. 2015;2015:793764. doi: 10.1155/2015/793764. Epub 2015 Mar 19.
8
Multivariate modeling identifies neutrophil- and Th17-related factors as differential serum biomarkers of chronic murine colitis.多变量建模确定中性粒细胞和 Th17 相关因素作为慢性鼠结肠炎的差异血清生物标志物。
PLoS One. 2010 Oct 19;5(10):e13277. doi: 10.1371/journal.pone.0013277.